Beckley Psytech News and Activities

Beckley Psytech is owned by AtaiBeckley.

AtaiBeckley is a company listed under the stock ticker ATAI (DE).

AtaiBeckley has a direct presence in 2 countries.

View the org chart displaying its 7 main executives

Most searched biographies at Beckley Psytech

• Cosmo Mellen, Chief Executive Officer
• Rob Hershberg, Director
• Gerd Kochendoerfer, Director

Popular executive movements at AtaiBeckley

• Anne Johnson who was Chief Financial Officer, becomes Chief Accounting Officer  (posted on February 19 2026).
• Michael Faerm has joined the company as Chief Financial Officer  (posted on February 19 2026).

Create your alert
to follow the executive moves at Beckley Psytech.

AtaiBeckley has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
• NewLimit has just announced a $435 Million fundraising (posted on June 3 2026).
• Rallybio and Avenzo Therapeutics have announced they will merge  (posted on June 1 2026)..

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Valerie Hanote - Non-Executive Director at Eurofins

Learn more about the Biotechnology industry

Press releases by Beckley Psytech

• atai Life Sciences and Beckley Psytech Report Positive Phase 2a Data Demonstrating Improved Outcomes with a Two-Dose Induction Regimen of BPL-003 in Patients with Treatment-Resistant Depression
• atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression
• Beckley Psytech announces positive topline data from Part 2 of its Phase IIa study of BPL-003 (intranasal 5-MeO-DMT benzoate) in combination with SSRIs for treatment resistant depression
• News
• Beckley Psytech Completes Enrolment in Phase IIb study of BPL-003 for Treatment Resistant Depression
• Beckley Psytech announces positive topline results from Phase IIa study of ELE-101 (IV psilocin benzoate) for Major Depressive Disorder
• Publications
• Beckley Psytech announces initial results from Phase I study and first patients dosed in Phase IIa study of ELE-101 (IV psilocin benzoate) for Major Depressive Disorder
• First patient dosed in Beckley Psytech’s Phase IIa study of BPL-003 in combination with SSRIs for Treatment Resistant Depression
• Beckley Psytech announces positive initial data from Phase IIa study of novel 5-MeO-DMT formulation BPL-003 for Treatment Resistant Depression
• View more press releases Close

Social media about Beckley Psytech

• Beckley Psytech on Wikipedia, Google News & Yahoo Finance
• Beckley Psytech on LinkedIn, X (Twitter) & YouTube